Congratulations to Charlottetown-based Pegasus Biotech Inc. as they embark on an important scientific collaboration with a consortium developing a cutting-edge vaccine for broader protection against influenza.

https://pegasusbio.com/press-release/influenza-research-consortium-announces-1-2-million-c2-2-million-in-funding-for-the-development-of-a-novel-broad-spectrum-influenza-vaccine

Over the two years, this new collaboration will employ next generation nucleic acid vaccine and delivery technologies, developed by 4basebio and Pegasus Biotech, to combine seasonal influenza vaccines with ConserV Bioscience’s antigens clinically proven to induce broadly protective immune responses.

This work is supported by the National Research Council Canada / Conseil national de recherches Canada in collaboration with the UK government 🇨🇦 🇬🇧